Versican, a major hyaluronan-binding component in the dermis, loses its hyaluronan-binding ability in solar elastosis.
Versican interacts with hyaluronan (HA) at its N-terminus and with fibrillin-1 at its C terminus. As versican in the dermis connects microfibrils to the HA-rich matrix for viscoelasticity, dermal diseases may involve destruction of these complexes. A recombinant versican protein, rVN, covering the HA binding region (HABR) of human versican and a polyclonal antibody, 6084, against rVN were prepared and characterized. Blotting analyses of skin extracts with 6084 and biotin-conjugated HA revealed that versican was a major HA-binding component in the dermis. Matrix metalloprotease-12, which is expressed in areas of solar elastosis, degraded versican and abrogated its HA-binding ability. Immunohistochemical analyses revealed that the elastic materials in solar elastosis lesions were negative for 6084, but positive for 2B1, an antibody recognizing the C-terminus of versican, indicating loss of the HABR in the aggregated elastic fibers. This loss of the HA-binding ability of versican followed by HA exclusion may be responsible for the pathological and phenotypical changes observed in solar elastosis.
Hasegawa
Keiko
K
Department of Biochemistry and Molecular Biology, Aichi Prefectural College of Nursing and Health, Nagoya, Aichi, Japan.
Yoneda
Masahiko
M
Kuwabara
Hiroko
H
Miyaishi
Osamu
O
Itano
Naoki
N
Ohno
Akiko
A
Zako
Masahiro
M
Isogai
Zenzo
Z
D000906:Antibodies / Q000276:immunology; D001665:Binding Sites / Q000276:immunology; D003238:Connective Tissue / Q000187:drug effects / Q000378:metabolism; D020405:Dermis / Q000187:drug effects / Q000378:metabolism*; D004547:Elastic Tissue / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D006820:Hyaluronic Acid / Q000378:metabolism*; D053508:Matrix Metalloproteinase 12 / Q000494:pharmacology; D020894:Microfibrils / Q000187:drug effects / Q000378:metabolism; D011485:Protein Binding / Q000502:physiology; D011994:Recombinant Proteins / Q000276:immunology; D015595:Skin Aging / Q000473:pathology* / Q000502:physiology*; D053675:Versicans / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*
D000906:Antibodies; D011994:Recombinant Proteins; D053675:Versicans; D006820:Hyaluronic Acid; D053508:Matrix Metalloproteinase 12